Authors
Latest:
Organization Rallies Global Oncology Community to Eliminate Cancer Health DisparitiesToday, more than half of new cancer cases and over two-thirds of cancer deaths occur in low- and middle-income countries.
Latest:
Dr. Desai on Phase I Study of Entrectinib in Solid TumorsAmi Vijay Desai, MD, assistant professor of Pediatrics, University of Chicago Comer Children's Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors.
Latest:
Dr. Mirhadi on Patient Populations of Lung Cancer Optimal for RadiationAmin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.
Latest:
Computer Model Personalizes Donor Selection for Stem Cell TransplantsInvestigators at Virginia Commonwealth University Massey Cancer Center are developing dynamical models that may allow clinicians to move beyond simple human leukocyte antigen matching to personalize immunosuppressive regimens and thus improve donor selection.
Latest:
Dr. Khan on Retrospective Analysis of Demographics in CRC and Gastric CancerAmir Khan, MD, discusses a large retrospective database analysis on colorectal cancer and gastric cancer presented at the 2020 Gastrointestinal Cancers Symposium.
Latest:
MicroRNA-34a in Hepatocellular CarcinomaAmira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).
Latest:
Dr. Desai on Immunotherapy in Patients With NSCLC and Low PD-L1 ExpressionAmishi Desai, MD, assistant professor of medicine at Upstate University Hospital, discusses the use of immunotherapy in patients with non–small cell lung cancer (NSCLC) with PD-L1 expression less than 1%.
Latest:
Future Directions in the Management of Hepatocellular CarcinomaTo close, Dr. Saeed and Dr. Singal share their excitement for the future landscape, emerging agents and treatment strategies for patients with HCC.
Latest:
Dr. Gupta on the Role of Surgery in Bladder CancerAmit Gupta, MD, urologic oncologist, Department of Surgery, Cedars-Sinai Medical Center, discusses how the use of immunotherapy agents is altering the role of surgery in bladder cancer and the need for Bacillus Calmette-Guérin (BCG) alternatives.
Latest:
CD19 CAR T-Cell Therapy Shows Efficacy in Real-World SettingInvestigators at Montefiore showed that axicabtagene-ciloleucel can be used successfully in ethnically diverse patients with high-risk, relapsed/refractory diffuse large B-cell lymphoma at an inner-city hospital.
Latest:
Pivotal Trial Results Look to Shake Up HCC TreatmentHepatocellular cancer, the most common primary liver malignancy, is the fourth-leading cause of cancer-related deaths globally.
Latest:
Final Thoughts on the Future of Liver CancerA panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.
Latest:
Optimizing Precision Medicine in HCCTakeaways from a discussion on treatment advances in hepatocellular carcinoma.
Latest:
Dr. Chak on Challenges With Screening For Esophageal CancerAmitabh Chak, MD, professor of Medicine, Gastroenterology, Case Western Reserve University School of Medicine, discusses challenges with screening patients for Barrett's esophagus and esophageal cancer.
Latest:
Update on the Management of Pain in Patients With Advanced CancerIn the United States in 2010, it was estimated that there were more than 1.5 million new cancer cases and 569,490 deaths from cancer.
Latest:
Dr. Narang Discusses Role of Radiation in Pancreatic CancerAmol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses the role of radiation therapy in the treatment of patients with pancreatic cancer.
Latest:
Dr Krishnan on the Optimal Use of DKd in Relapsed/Refractory Multiple MyelomaAmrita Krishnan, MD, discusses the role of DKd for patients with relapsed/refractory multiple myeloma.
Latest:
Dr. Heimberger on the Variability of Responses in GlioblastomaAmy B. Heimberger, MD, discusses the variability of responses in glioblastoma.
Latest:
Common Adverse Effects of Anti-HER2 Therapies and Practical Management RecommendationsThe benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.
Latest:
Dr. Duffield on Implications for Immunotherapy in Nasopharyngeal CarcinomaAmy Duffield, MD, PhD, assistant professor of pathology, Johns Hopkins University School of Medicine, member, Johns Hopkins Kimmel Cancer Center, discusses the implications for immunotherapy in nasopharyngeal carcinoma.
Latest:
Practical Questions on Checkpoint Agents AriseDespite the promising developments in this arena, many patients with cancer respond inadequately to immune checkpoint monotherapy, and others develop serious (grade 3-4) toxicities that require treatment cessation.
Latest:
Dr. Abernethy Discusses Anamorelin as a Treatment Option for Patients with Cancer Anorexia-CachexiaAmy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses anamorelin for the treatment of cancer anorexia-cachexia.
Latest:
The Benefits for Nurses of Using Psychosocial Cancer Registry DataRegistries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.
